Literature DB >> 21149624

In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus.

Enrique Calvo1, F Javier Pastor, Emilio Mayayo, Valentina Salas, Josep Guarro.   

Abstract

Anidulafungin (AFG) showed high activity against 27 strains of Aspergillus flavus by use of broth microdilution and disk diffusion methods. This drug was effective in vivo in a murine model of disseminated infection with five isolates tested. AFG was able to prolong survival and reduce tissue burden of infected mice but not able to reduce galactomannan serum concentrations. The AFG serum levels were above the corresponding minimum effective concentrations (MEC) for all of the strains tested.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21149624      PMCID： PMC3067077          DOI： 10.1128/AAC.01282-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program.

Authors:  J Morgan; K A Wannemuehler; K A Marr; S Hadley; D P Kontoyiannis; T J Walsh; S K Fridkin; P G Pappas; D W Warnock
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

2.  Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.

Authors:  Rocus R Klont; Monique A S H Mennink-Kersten; Dorien Ruegebrink; Antonius J M M Rijs; Nicole M A Blijlevens; J Peter Donnelly; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2006-06-19       Impact factor: 9.079

Review 3.  [Systemic antifungals. Pharmacodynamics and pharmacokinetics].

Authors:  Mercedes Catalán; Juan Carlos Montejo
Journal:  Rev Iberoam Micol       Date:  2006-03       Impact factor: 1.044

4.  Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.

Authors:  Edward Sionov; Sonia Mendlovic; Esther Segal
Journal:  J Infect       Date:  2005-12-19       Impact factor: 6.072

5.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 6.  Anidulafungin: a novel echinocandin.

Authors:  Jose A Vazquez; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2006-06-09       Impact factor: 9.079

7.  Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.

Authors:  J Roberts; K Schock; S Marino; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

Review 10.  Aspergillus flavus: human pathogen, allergen and mycotoxin producer.

Authors:  M T Hedayati; A C Pasqualotto; P A Warn; P Bowyer; D W Denning
Journal:  Microbiology (Reading)       Date:  2007-06       Impact factor: 2.777
View more
  6 in total

1.  Current role of echinocandins in the management of invasive aspergillosis.

Authors:  Małgorzata Mikulska; Claudio Viscoli
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

Authors:  Enrique Calvo; F Javier Pastor; Valentina Salas; Emilio Mayayo; Josep Guarro
Journal:  Mycopathologia       Date:  2011-12-04       Impact factor: 2.574

3.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

4.  Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Emilio Mayayo; Guillermo Quindós; Alfonso J Carrillo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

5.  Evaluation of the efficacies of Amphotericin B, Posaconazole, Voriconazole, and Anidulafungin in a murine disseminated infection by the emerging opportunistic Fungus Sarocladium (Acremonium) kiliense.

Authors:  Fabiola Fernández-Silva; Javier Capilla; Emilio Mayayo; Deanna A Sutton; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

Review 6.  Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management.

Authors:  Shivaprakash M Rudramurthy; Raees A Paul; Arunaloke Chakrabarti; Johan W Mouton; Jacques F Meis
Journal:  J Fungi (Basel)       Date:  2019-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.